1887

Abstract

The postantibiotic effect (PAE) of tomopenem was determined after a 2 h exposure of two strains of meticillin-susceptible and meticillin-resistant (MSSA and MRSA), and imipenem-susceptible and imipenem-resistant , to tenfold the respective MIC. The PAEs on MSSA and were approximately 1 h and they were comparable to those of meropenem. The PAE on MRSA was 1.5 to 3 h, equal to or longer than those of vancomycin. The PAEs of tomopenem not only were found for MRSA, but also were present in the imipenem-resistant tested.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.017905-0
2010-04-01
2019-10-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/4/438.html?itemId=/content/journal/jmm/10.1099/jmm.0.017905-0&mimeType=html&fmt=ahah

References

  1. Bax, R. P., Bastain, W., Featherstone, A., Wilkinson, D. M.,Hutchison, M. & Haworth, S. J. ( 1989; ). The pharmacokineticsof meropenem in volunteers. J Antimicrob Chemother 24 (Suppl. A), 311–320.
    [Google Scholar]
  2. CLSI ( 2006; ). Methods for DilutionAntimicrobial Susceptibility Tests for Bacteria that Grow Aerobically,7th edn, approved standard M7–A7. Wayne, PA: Clinical and LaboratoryStandards Institute.
  3. Craig, W. A. & Gudmundsson, S. ( 1996; ). The postantibiotic effect. In Antibiotics in Laboratory Medicine, 4th edn, pp. 296–329. Edited by V. Lorian. Baltimore, MD: Williams &Wilkins.
  4. Drusano, G. L. & Standiford, H. C. ( 1985; ). Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med 78 (Suppl. 6A), 47–53.
    [Google Scholar]
  5. Gould, I. M., Jason, A. C. & Milne, K. ( 1989; ). Use of the Malthus microbial growth analyser to study the postantibiotic effect of antibiotics. J Antimicrob Chemother 24, 523–531.[CrossRef]
    [Google Scholar]
  6. Hanssen, A. M. & Ericson Solid, J. U. ( 2006; ). SCCmec in staphylococci: genes on the move. FEMS Immunol Med Microbiol 46, 8–20.[CrossRef]
    [Google Scholar]
  7. Koga, T., Abe, T., Inoue, H., Takenouchi, T., Kitayama, A.,Yoshida, T., Masuda, N., Sugihara, C., Kakuta, M. & other authors ( 2005; ). In vitro and in vivo antibacterial activity of CS-023 (RO4908463),a novel parenteral carbapenem. Antimicrob Agents Chemother 49, 3239–3250.[CrossRef]
    [Google Scholar]
  8. Koga, T., Masuda, N., Kakuta, M., Namba, E., Sugihara, C. &Fukuoka, T. ( 2008; ). Potent in vitro activityof tomopenem (CS-023) against methicillin-resistant Staphylococcusaureus and Pseudomonas aeruginosa. Antimicrob AgentsChemother 52, 2849–2854.
    [Google Scholar]
  9. Koga, T., Sugihara, C., Kakuta, M., Masuda, N., Namba, E. &Fukuoka, T. ( 2009; ). Affinity of tomopenem (CS-023)for penicillin-binding proteins in Staphylococcus aureus, Escherichiacoli, and Pseudomonas aeruginosa. Antimicrob AgentsChemother 53, 1238–1241.
    [Google Scholar]
  10. MacGowan, A. P., Bowker, K. E. & Noel, A. R. ( 2008; ). Pharmacodynamics of the antibacterial effect and emergenceof resistance to tomopenem, formerly RO4908463/CS-023, in an in vitropharmacokinetic model of Staphylococcus aureus infection. Antimicrob Agents Chemother 52, 1401–1406.[CrossRef]
    [Google Scholar]
  11. Odenholt, I., Isaksson, B., Nilsson, L. & Cars, O. ( 1989; ). Postantibiotic and bactericidal effect of imipenemagainst Pseudomonas aeruginosa. Eur J Clin Microbiol InfectDis 8, 136–141.
    [Google Scholar]
  12. Odenholt-Tornqvist, I., Löwdin, E. & Cars, O. ( 1991; ). Pharmacodynamic effects of subinhibitory concentrationsof β-lactam antibiotics in vitro. Antimicrob AgentsChemother 35, 1834–1839.
    [Google Scholar]
  13. Ohya, S., Abe, T., Ishii, C., Kakuta, M., Masuda, N., Utsui,Y. & Kuwahara, S. ( 2000; ). R-115685, a novel parenteralcarbapenem: in vitro antibacterial activity. In Program and Abstractsof the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract F-1230. Toronto, Canada: American Society for Microbiology.
  14. Quale, J., Bratu, S., Gupta, J. & Landman, D. ( 2006; ). Interplay of efflux system, ampC, and oprD expression incarbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50, 1633–1641.[CrossRef]
    [Google Scholar]
  15. Sesoko, S., Morita, K., Tajima, N. & Nakashima, M. ( 2006; ). Safety, tolerability, and pharmacokinetics (PK)of CS-023, a new parenteral carbapenem, in healthy Japanese male volunteers.In Program and Abstracts of the 42nd Interscience Conference on AntimicrobialAgents and Chemotherapy, abstract A-1941. San Francisco: American Societyfor Microbiology.
  16. Shibayama, T., Matsushita, Y., Hirota, T., Ikeda, T. & Kuwahara,S. ( 2006; ). Pharmacokinetics of CS-023 (RO4908463),a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob Agents Chemother 50, 4186–4188.[CrossRef]
    [Google Scholar]
  17. Shibayama, T., Matsushita, Y., Kurihara, A., Hirota, T. &Ikeda, T. ( 2007; ). Prediction of pharmacokinetics ofCS-023 (RO4908463), a novel parenteral carbapenem antibiotic, inhumans using animal data. Xenobiotica 37, 91–102.[CrossRef]
    [Google Scholar]
  18. Vogelman, B. S. & Craig, W. A. ( 1985; ). Postantibiotic effects. J Antimicrob Chemother 15 (Suppl. A), 37–46.[CrossRef]
    [Google Scholar]
  19. Zhanel, G. G., Hoban, D. J. & Harding, G. K. M. ( 1991; ). The postantibiotic effect: a review of in vitro andin vivo data. DICP 25, 153–163.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.017905-0
Loading
/content/journal/jmm/10.1099/jmm.0.017905-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error